New drug approved for metastatic prostate cancer

Questions To Ask Your Health Care Provider

• Am I a candidate for PSMA imaging?
• Am I a candidate for PSMA-targeted therapy?
• Am I a candidate for other therapies for mCRPC, such as a PARP inhibitor?
• Should I have genetic testing?
• Should I have tumor testing?

Open Clinical Trials

The following studies are looking at PARP inhibitors and similar agents for treating people with advanced prostate cancer.  

• NCT05932862: Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors. The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors, including breast cancer. 
• NCT05005728: XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. This study will look at the safety and clinical activity of the drug XmAb20717 alone or in combination with standard-of-care anticancer therapies in patients with metastatic castration-resistant prostate cancer who have been treated with at least 2 prior lines of treatment.
• NCT03317392: Studying the Medication Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis. This study is measuring the best dosage for and side effects of the drug combination olaparib and radium-223 to treat men with mCRPC that has spread to the bones. 
• NCT05417594: Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study). This study is looking at a new PARP inhibitor called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. 

Other clinical trials for people with prostate cancer can be found here.

The following studies are looking at treatment for metastatic prostate cancer using PSMA-targeted therapies.  

• NCT05204927: Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer. This study will compare Lutetium 177Lu-PSMA-I&T to standard-of-care hormone therapy as treatment for men with metastatic castration-resistant prostate cancer.
• NCT03724747: Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer. This study is looking at the safety and dosage of the investigational drug (BAY 2315497 Injection) which targets cancers expressing prostate-specific membrane antigen (PSMA). BAY2315497 Injection will be given alone, or in combination with darolutamide.
• NCT04647526: Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH). The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed after treatment with androgen receptor axis-targeted therapy (ARAT).
• NCT04249947: P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC). This study is looking at treatment using a type of immunotherapy known as CAR-T for treating metastatic prostate cancer that expresses PSMA.

Other clinical trials for people with prostate cancer can be found here.